These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32438450)

  • 1. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
    Day JW; Fox TA; Halsey R; Carpenter B; Kottaridis PD
    Br J Haematol; 2020 Jul; 190(2):e80-e83. PubMed ID: 32438450
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.
    Dimopoulos G; de Mast Q; Markou N; Theodorakopoulou M; Komnos A; Mouktaroudi M; Netea MG; Spyridopoulos T; Verheggen RJ; Hoogerwerf J; Lachana A; van de Veerdonk FL; Giamarellos-Bourboulis EJ
    Cell Host Microbe; 2020 Jul; 28(1):117-123.e1. PubMed ID: 32411313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking IL-1 to prevent respiratory failure in COVID-19.
    van de Veerdonk FL; Netea MG
    Crit Care; 2020 Jul; 24(1):445. PubMed ID: 32682440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.
    González-García A; García-Sánchez I; Lopes V; Moreno-Arrones OM; Tortosa-Cabañas M; Elías-Sáenz I; Hernández-Rodríguez J
    Rheumatology (Oxford); 2020 Aug; 59(8):2171-2173. PubMed ID: 32568376
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.
    Pontali E; Volpi S; Antonucci G; Castellaneta M; Buzzi D; Tricerri F; Angelelli A; Caorsi R; Feasi M; Calautti F; Castagnola E; Rollandi GA; Ravelli A; Cassola G; Gattorno M
    J Allergy Clin Immunol; 2020 Jul; 146(1):213-215. PubMed ID: 32437739
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of anakinra in severe COVID-19: A case report.
    Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
    Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra: a silver lining in COVID-19?
    Gupta R
    Crit Care; 2020 Oct; 24(1):598. PubMed ID: 33023646
    [No Abstract]   [Full Text] [Related]  

  • 9. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
    Bilia S; Giannini D; Rizzelli GML; Tavoni A
    Clin Exp Rheumatol; 2020; 38(3):579. PubMed ID: 32456767
    [No Abstract]   [Full Text] [Related]  

  • 10. Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report.
    Karadeniz H; Yamak BA; Özger HS; Sezenöz B; Tufan A; Emmi G
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):883-885. PubMed ID: 32734502
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Ranger A; Haji R; Kaczmarski R; Danga A
    Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?
    Imazio M; Andreis A; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2020 Jul; 21(7):465-466. PubMed ID: 32487869
    [No Abstract]   [Full Text] [Related]  

  • 13. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
    Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G
    Proc Natl Acad Sci U S A; 2020 Aug; 117(32):18951-18953. PubMed ID: 32699149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A plea for the pathogenic role of immune complexes in severe Covid-19.
    Vuitton DA; Vuitton L; Seillès E; Galanaud P
    Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
    [No Abstract]   [Full Text] [Related]  

  • 15. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
    Assimakopoulos SF; Seintis F; Marangos M
    Med Hypotheses; 2020 Oct; 143():109926. PubMed ID: 32485316
    [No Abstract]   [Full Text] [Related]  

  • 16. Haemophagocytosis in bone marrow aspirates in patients with COVID-19.
    Debliquis A; Harzallah I; Mootien JY; Poidevin A; Labro G; Mejri A; Lamarque M; Kuteifan K; Drénou B
    Br J Haematol; 2020 Jul; 190(2):e70-e73. PubMed ID: 32529634
    [No Abstract]   [Full Text] [Related]  

  • 17. Rhabdomyolysis as Potential Late Complication Associated with COVID-19.
    He YC; Chen F
    Emerg Infect Dis; 2020 Sep; 26(9):2297-2298. PubMed ID: 32818421
    [No Abstract]   [Full Text] [Related]  

  • 18. Haemophagocytic lymphohistiocytosis in COVID-19 cases?
    Tveiten H; Aukrust P; Lehne G; Rodriguez JR; Skjønsberg OH
    Tidsskr Nor Laegeforen; 2020 Apr; 140(6):. PubMed ID: 32321221
    [No Abstract]   [Full Text] [Related]  

  • 19. [Chronic granulocytic leukemia with COVID-19 pneumonia: a case report].
    Sheng LS; Li DJ; Zhou JF; Huang W
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):601-602. PubMed ID: 32394688
    [No Abstract]   [Full Text] [Related]  

  • 20. COVID-19 and childhood acute lymphoblastic leukemia.
    Taub JW; Ge Y; Xavier AC
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28400. PubMed ID: 32400927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.